Share Price | Rani Therapeutics Holdings, Inc. Stock Analysis & Recommendation

Q: Is Rani Therapeutics Holdings, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Rani Therapeutics Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. However, moving averages are bearish on the daily, and Bollinger Bands are bearish on both weekly and monthly time frames. KST is mildly bullish weekly but bearish monthly, and Dow Theory indicates a mildly bullish stance monthly with no trend weekly. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -64.85% versus the S&P 500's 12.22%, and a one-year return of -79.06% compared to 17.14% for the index.

Q: Is Rani Therapeutics Holdings, Inc. overvalued or undervalued?

As of 31 March 2025, the valuation grade for Rani Therapeutics Holdings, Inc. has moved from does not qualify to risky. The company is currently considered overvalued given its negative financial metrics and significant losses. Key ratios include a Price to Book Value of -10.54, an EV to EBIT of -0.80, and an EV to EBITDA of -0.82, all indicating severe financial distress.In comparison to peers, Rani Therapeutics has a valuation of risky with a P/E ratio that is not applicable due to losses, while Avrobio, Inc. and Spero Therapeutics, Inc. are also classified as does not qualify and risky, respectively, with P/E ratios of -6.6206 and -2.3598. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -64.23% compared to the index's 2.44%, reinforcing the notion that Rani Therapeutics is overvalued in its current state.

Q: How big is Rani Therapeutics Holdings, Inc.?

Market Cap: As of Jun 18, Rani Therapeutics Holdings, Inc. has a market capitalization of 29.57 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Rani Therapeutics reported net sales of 1.20 million and a net profit of -54.54 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.99 million and total assets of 36.63 million.

Q: What does Rani Therapeutics Holdings, Inc. do?

Overview: Rani Therapeutics Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) Market-cap: USD 29.57 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.93 Return on Equity: 1,663.25% Price to Book: -9.68Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Should I buy, sell or hold Rani Therapeutics Holdings, Inc.?

Based on the current analysis of Rani Therapeutics Holdings, Inc., it would be advisable to consider selling your shares. The company is facing significant challenges, including a negative book value and weak long-term fundamental strength. Its net sales growth has been modest at an annual rate of 17.08%, but the operating profit is concerningly low at -230.91%. Additionally, the company's ability to manage its debt is weak, highlighted by a poor EBIT to interest ratio of -25.70. The negative EBITDA further adds to the risk associated with the stock. While it has generated a return of 0% over the past year, profits have only increased by 22.8%, which may not be sufficient to offset the underlying issues.Given these factors, holding or buying more shares could expose you to further risk, making selling a more prudent option at this time.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

120.78 k

Shareholding (Jun 2026)

FII

4.57%

Held by 26 FIIs

DII

78.41%

Held by 12 DIIs

Promoter

17.03%

Is Rani Therapeutics Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Rani Therapeutics Holdings, Inc. has a mildly bearish trend, with mixed indicators showing mild bullishness in MACD and KST but bearish signals in moving averages and Bollinger Bands, while the stock has underperformed the S&P 500 significantly, with a year-to-date return of -64.85%.

View full answer

Is Rani Therapeutics Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of March 31, 2025, Rani Therapeutics Holdings, Inc. is classified as risky and overvalued due to negative financial metrics, including a Price to Book Value of -10.54 and a year-to-date return of -64.23%, significantly underperforming the S&P 500.

View full answer

How big is Rani Therapeutics Holdings, Inc.?

22-Jun-2025

As of Jun 18, Rani Therapeutics Holdings, Inc. has a market capitalization of 29.57 million and reported net sales of 1.20 million with a net profit of -54.54 million over the last four quarters. The company has shareholder's funds of 1.99 million and total assets of 36.63 million as of Dec 24.

View full answer

What does Rani Therapeutics Holdings, Inc. do?

22-Jun-2025

Rani Therapeutics Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $13 million as of March 2025. The company has a market cap of $29.57 million and does not pay dividends.

View full answer

Should I buy, sell or hold Rani Therapeutics Holdings, Inc.?

22-Jun-2025

Compare Rani Therapeutics Holdings, Inc. with Similar Stocks

Aspira Women's Health, Inc.CEL-SCI Corp.Intensity Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Operating Profit of 5.76%, the company declared Very Positive results in Jun 26

The company has declared positive results for the last 8 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD -20.3 MM
NET SALES(HY) Higher at USD 3.42 MM
NET PROFIT(HY) Higher at USD -14.42 MM

Risky -

Rising Promoter Confidence

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 100 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.46

Return on Equity

-122.31%

Price to Book

3.04

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Jun 2026)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.59%

6 Months

-32.72%

1 Year

59.76%

2 Years

-64.82%

3 Years

-72.41%

4 Years

-91.64%

5 Years

-95.75%

Rani Therapeutics Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

18.94%

EBIT Growth (5y)

-184.80%

EBIT to Interest (avg)

-25.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.93

Sales to Capital Employed (avg)

0.08

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

52.91%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.04

EV to EBIT

-1.36

EV to EBITDA

-1.39

EV to Capital Employed

-3.39

EV to Sales

31.81

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-122.31%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (5.81%)

Foreign Institutions

Held by 26 Foreign Institutions (4.57%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 0.00% vs 13.33% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -5.00% vs 12.09% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.70",
          "val2": "1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.60",
          "val2": "-8.20",
          "chgp": "-4.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.40",
          "val2": "-8.00",
          "chgp": "-5.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,168.60%",
          "val2": "-4,882.30%",
          "chgp": "-28.63%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 60.00% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 27.56% vs 16.64% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.60",
          "val2": "1.00",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-37.40",
          "val2": "-48.60",
          "chgp": "23.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.90",
          "val2": "5.00",
          "chgp": "-42.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-3.70",
          "chgp": "83.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.00",
          "val2": "-56.60",
          "chgp": "27.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-23,459.90%",
          "val2": "-48,249.00%",
          "chgp": "2,478.91%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]